Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INGN
Previous Symbol
CUSIPN/A
Phone805-562-0500
Debt
Debt-to-Equity RatioN/A
Current Ratio6.49
Quick Ratio5.83
Price-To-Earnings
Trailing P/E Ratio106.11
Forward P/E Ratio66.20
P/E Growth2.72
Sales & Book Value
Annual Sales$249.44 million
Price / Sales11.90
Cash Flow$1.9458 per share
Price / Cash71.44
Book Value$13.64 per share
Price / Book10.19
Profitability
EPS (Most Recent Fiscal Year)$1.31
Net Income$21 million
Net Margins12.28%
Return on Equity18.91%
Return on Assets15.43%
Miscellaneous
Employees770
Outstanding Shares21,350,000
Market Cap$2.99 billion
OptionableOptionable
Inogen (NASDAQ:INGN) Frequently Asked Questions
What is Inogen's stock symbol?
Inogen trades on the NASDAQ under the ticker symbol "INGN."
How were Inogen's earnings last quarter?
Inogen Inc (NASDAQ:INGN) announced its quarterly earnings data on Tuesday, November, 6th. The medical technology company reported $0.73 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.52 by $0.21. The medical technology company had revenue of $95.29 million for the quarter, compared to the consensus estimate of $90.94 million. Inogen had a net margin of 12.28% and a return on equity of 18.91%. The company's revenue was up 38.0% on a year-over-year basis. During the same period last year, the firm earned $0.33 EPS. View Inogen's Earnings History.
When is Inogen's next earnings date?
What guidance has Inogen issued on next quarter's earnings?
Inogen updated its FY 2018 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $345-355 million, compared to the consensus revenue estimate of $349.97 million.Inogen also updated its FY 2019 guidance to EPS.
What price target have analysts set for INGN?
6 brokerages have issued 1-year price objectives for Inogen's stock. Their predictions range from $170.00 to $290.00. On average, they anticipate Inogen's stock price to reach $235.60 in the next twelve months. This suggests a possible upside of 69.5% from the stock's current price. View Analyst Price Targets for Inogen.
What is the consensus analysts' recommendation for Inogen?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inogen.
What are Wall Street analysts saying about Inogen stock?
Here are some recent quotes from research analysts about Inogen stock:
- 1. Needham & Company LLC analysts commented, "INGN beat consensus revenue and EPS expectations in 3Q18 and management raised guidance for revenue and net income. The revenue upside was mainly driven by the DTC sales force expansion. Gross margin was up Y/ Y and beat our estimate while operating margin was down Y/Y and just missed our estimate. INGN continues to see the benefit of its DTC sales force expansion as DTC sales grew 66% in 3Q18 and management reiterated its plans to expand its Cleveland sales team to ~330 reps. We expect the ongoing sales force expansion, new product cycle, and the market shift to POCs to sustain strong growth and drive additional upside to consensus and we reiterate our Buy rating." (11/7/2018)
- 2. According to Zacks Investment Research, "Inogen outperformed its industry in a year’s time. Solid business-to-business sales in the United States is a major positive. Strong growth of the unit in Europe also buoys optimism. In fact, management expects to see strength in Europe in the quarters ahead. Management is also upbeat about strong contributions from the company’s core direct-to-consumer unit. The company’s increasing hiring in Cleveland is indicative of brighter prospects ahead. Recently, the company replaced Rollins in the S&P MidCap 400 bandwagon. On the flip side, Inogen’s rental revenues have been soft lately. In fact, management expects rental revenues to remain low throughout 2018. Rising operating expenses are discouraging as well. This is likely to keep margins under pressure. Stiff competition in the MedTech space is likely to mar prospects." (9/27/2018)
Has Inogen been receiving favorable news coverage?
News coverage about INGN stock has trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Inogen earned a coverage optimism score of 0.5 on InfoTrie's scale. They also gave media headlines about the medical technology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
Are investors shorting Inogen?
Inogen saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 1,586,018 shares, an increase of 43.3% from the September 28th total of 1,106,604 shares. Based on an average trading volume of 435,432 shares, the short-interest ratio is presently 3.6 days. Currently, 9.0% of the shares of the company are short sold. View Inogen's Current Options Chain.
Who are some of Inogen's key competitors?
Some companies that are related to Inogen include Steris (STE), WILLIAM DEMANT/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Avanos Medical (AVNS), Establishment Labs (ESTA), Sientra (SIEN), RTI Surgical (RTIX), Invacare (IVC), Lakeland Industries (LAKE), ConforMIS (CFMS), Rewalk Robotics (RWLK), COLLPLANT HOLDI/S (CLGN), NanoVibronix (NAOV) and Histogenics (HSGX).
Who are Inogen's key executives?
Inogen's management team includes the folowing people:
- Mr. Scott Wilkinson, CEO, Pres & Director (Age 53)
- Mr. Brenton Taylor, Exec. VP of Engineering (Age 37)
- Ms. Alison Perry Bauerlein, Exec. VP of Fin., CFO, Corp. Sec. & Treasurer (Age 37)
- Mr. Matthew S. Scribner, Exec. Officer (Age 51)
- Mr. Byron Myers, Exec. VP of Sales & Marketing (Age 39)
Who are Inogen's major shareholders?
Inogen's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.02%), Blair William & Co. IL (1.92%), Alliancebernstein L.P. (1.75%), Renaissance Technologies LLC (1.72%), Dimensional Fund Advisors LP (1.68%) and Bank of New York Mellon Corp (0.97%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen.
Which institutional investors are selling Inogen stock?
INGN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Peregrine Capital Management LLC, Blair William & Co. IL, WINTON GROUP Ltd, Thrivent Financial for Lutherans, Rockefeller Capital Management L.P. and Wells Fargo & Company MN. Company insiders that have sold Inogen company stock in the last year include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Insider Buying and Selling for Inogen.
Which institutional investors are buying Inogen stock?
INGN stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Partner Fund Management L.P., Carillon Tower Advisers Inc., Copper Rock Capital Partners LLC, Alliancebernstein L.P., Deutsche Bank AG, Renaissance Technologies LLC and Jane Street Group LLC. View Insider Buying and Selling for Inogen.
How do I buy shares of Inogen?
Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inogen's stock price today?
One share of INGN stock can currently be purchased for approximately $139.01.
How big of a company is Inogen?
Inogen has a market capitalization of $2.99 billion and generates $249.44 million in revenue each year. The medical technology company earns $21 million in net income (profit) each year or $1.31 on an earnings per share basis. Inogen employs 770 workers across the globe.
What is Inogen's official website?
How can I contact Inogen?
Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]
MarketBeat Community Rating for Inogen (NASDAQ INGN)
MarketBeat's community ratings are surveys of what our community members think about Inogen and other stocks. Vote "Outperform" if you believe INGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
